In a nutshell
Da Volterra is a private clinical-stage biopharmaceutical company which innovates for better health and care for people worldwide.
Our team is composed of 45 people with an extensive experience in science and in the industrial development of medical products. Together, we are dedicated to developing novel and safe therapeutic options for patients.
Our expertise focuses on the protection of the intestinal microbiome in cancer patients.
- Based in Paris, France
- 45 collaborators,
- $94M funds raised
- Microbiome Protection in Oncology
Da Volterra’s goal is to develop and commercialize innovative healthcare solutions to preserve the intestinal microbiome of patients worldwide and help prevent and cure life-threatening diseases.
As new insights into the human intestinal microbiome are fundamentally reshaping how we understand and treat a wide range of diseases, Da Volterra is a pioneer in understanding and harnessing the microbiome capacity to help prevent and cure diseases, notably in cancer patients.
Our mission & vision
Da Volterra’s vision is to be a trusted and acknowledged leader of drug and medical device development in the microbiome field.
Our mission is to discover and develop up-to-market safe and novel therapeutic options, preserving patients’ microbiome to prevent and cure life-threatening diseases.
We strive to serve patients by transforming the promise of science into innovative treatments which have the power to restore health and save lives.